Literature DB >> 1415145

The harm reduction approach and risk factors for human immunodeficiency virus (HIV) seroconversion in injecting drug users, Amsterdam.

E J van Ameijden1, J A van den Hoek, H J van Haastrecht, R A Coutinho.   

Abstract

To assess risk factors for seroconversion to human immunodeficiency virus, the authors studied a cohort of human immunodeficiency virus-seronegative injecting drug users in Amsterdam, the Netherlands, between December 1985 and November 1991. The behaviors of 31 seroconverters were compared with those of 202 seronegative injecting drug users (controls). Three independent risk factors for seroconversion were found in logistic regression: 1) living greater than 10 years in Amsterdam (odds ratio (OR) = 2.45, 95% confidence interval (CI) 1.09-5.53); 2) first injection less than or equal to 2 years ago (OR = 3.43, 95% CI 1.20-9.81); and 3) injecting mainly at home (OR = 0.39, 95% CI 0.18-0.88). No evidence was found that receiving daily methadone treatments at methadone posts and obtaining new needles/syringes via the exchange program were protective. However, the data suggest that exchanging needles may have been protective at the start of this program. Influencing injecting drug users to modify behavior to prevent new infections appears to be very difficult, and it may, therefore, be important to increase preventive efforts targeted at the sexual partners of injecting drug users.

Entities:  

Mesh:

Year:  1992        PMID: 1415145     DOI: 10.1093/oxfordjournals.aje.a116489

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  19 in total

1.  Large decline in injecting drug use in Amsterdam, 1986-1998: explanatory mechanisms and determinants of injecting transitions.

Authors:  E J van Ameijden; R A Coutinho
Journal:  J Epidemiol Community Health       Date:  2001-05       Impact factor: 3.710

2.  Knowledge of HIV serostatus and preventive behaviour among European injecting drug users: second study. European Community Study Group on HIV in Injecting Drug Users.

Authors:  M G Schlumberger; J C Desenclos; G Papaevangelou; S C Richardson; R Ancelle-Park
Journal:  Eur J Epidemiol       Date:  1999-03       Impact factor: 8.082

3.  Volunteer bias in nonrandomized evaluations of the efficacy of needle-exchange programs.

Authors:  H Hagan; J P McGough; H Thiede; S G Hopkins; N S Weiss; E R Alexander
Journal:  J Urban Health       Date:  2000-03       Impact factor: 3.671

4.  Factors associated with adolescent initiation of injection drug use.

Authors:  C M Fuller; D Vlahov; A M Arria; D C Ompad; R Garfein; S A Strathdee
Journal:  Public Health Rep       Date:  2001       Impact factor: 2.792

5.  Selection effect of needle exchange in Anchorage, Alaska.

Authors:  Dennis G Fisher; Grace L Reynolds; Colin R Harbke
Journal:  J Urban Health       Date:  2002-03       Impact factor: 3.671

6.  The role of epidemiology in needle exchange programs.

Authors:  D Des Vlahov
Journal:  Am J Public Health       Date:  2000-09       Impact factor: 9.308

7.  Diffusion of the D.A.R.E and syringe exchange programs.

Authors:  Don C Des Jarlais; Zili Sloboda; Samuel R Friedman; Barbara Tempalski; Courtney McKnight; Naomi Braine
Journal:  Am J Public Health       Date:  2006-06-29       Impact factor: 9.308

8.  Injecting risk behavior among drug users in Amsterdam, 1986 to 1992, and its relationship to AIDS prevention programs.

Authors:  E J van Ameijden; A R van den Hoek; R A Coutinho
Journal:  Am J Public Health       Date:  1994-02       Impact factor: 9.308

Review 9.  The role of needle exchange programs in HIV prevention.

Authors:  D Vlahov; B Junge
Journal:  Public Health Rep       Date:  1998-06       Impact factor: 2.792

Review 10.  Fifteen years of research on preventing HIV infection among injecting drug users: what we have learned, what we have not learned, what we have done, what we have not done.

Authors:  D C Des Jarlais; S R Friedman
Journal:  Public Health Rep       Date:  1998-06       Impact factor: 2.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.